HBM Partner Plans Nasdaq Listing for Drug Development Subsidiary in 2027

MT Newswires Live11-18 13:49

HBM Holdings (HKG:2142) said its U.S. partner, Spruce Biosciences, plans to list a newly established subsidiary focused on developing its experimental drug CRHX-101 on Nasdaq in the first half of 2027.

Spruce Biosciences has separated the CRHX-101 program into Adrenyx Biosciences, a wholly owned subsidiary, according to a Wednesday Hong Kong bourse filing. HBM expects to hold equity interests in both companies.

CRHX-101 is an experimental monoclonal antibody being developed to treat classic congenital adrenal hyperplasia. Adrenyx intends to submit an investigational new drug application to the U.S. Food and Drug Administration and begin clinical development thereafter.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment